Sarepta Therapeutics Inc. (NASDAQ:SRPT) has been given a $68.00 price target by equities research analysts at Piper Jaffray Cos. in a research note issued to investors on Tuesday. The brokerage currently has a a “buy” rating on the stock. Piper Jaffray Cos.’s price target suggests a potential upside of 10.61% from the company’s previous close.

A number of other equities analysts also recently commented on SRPT. Oppenheimer Holdings Inc. restated a “buy” rating and set a $60.00 price objective on shares of Sarepta Therapeutics in a research note on Sunday, July 17th. Jefferies Group set a $58.00 target price on shares of Sarepta Therapeutics and gave the company a “hold” rating in a research note on Sunday. Vetr downgraded shares of Sarepta Therapeutics from a “buy” rating to a “strong sell” rating and set a $17.28 target price for the company. in a research note on Wednesday, June 8th. JMP Securities reiterated an “underperform” rating and issued a $10.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, September 15th. Finally, Cowen and Company reiterated a “hold” rating on shares of Sarepta Therapeutics in a research note on Tuesday, June 7th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $58.12.

Sarepta Therapeutics (NASDAQ:SRPT) traded up 1.58% during midday trading on Tuesday, reaching $62.45. The company’s stock had a trading volume of 1,188,802 shares. The firm’s market cap is $2.99 billion. The firm has a 50 day moving average price of $37.94 and a 200-day moving average price of $24.60. Sarepta Therapeutics has a 52 week low of $8.00 and a 52 week high of $63.73.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same period in the prior year, the business posted ($0.87) EPS. On average, analysts forecast that Sarepta Therapeutics will post ($4.16) earnings per share for the current fiscal year.

In related news, CEO Edward M. Md Kaye sold 24,557 shares of Sarepta Therapeutics stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now owns 76,983 shares of the company’s stock, valued at $2,309,490. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Jayant Aphale sold 35,000 shares of Sarepta Therapeutics stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the transaction, the vice president now directly owns 21,490 shares of the company’s stock, valued at approximately $1,074,500. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.

A number of institutional investors have recently made changes to their positions in SRPT. Vanguard Group Inc. increased its position in shares of Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock worth $59,227,000 after buying an additional 161,790 shares in the last quarter. State Street Corp increased its position in shares of Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock worth $58,976,000 after buying an additional 625,051 shares in the last quarter. BlackRock Fund Advisors increased its position in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock valued at $20,865,000 after buying an additional 25,799 shares during the period. Finally, Franklin Resources Inc. bought a new stake in Sarepta Therapeutics during the first quarter valued at $13,506,000. 65.29% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.